From the article, it reads that this is in direct competition to Amgen. Imagine if the OnCarlytics/Blincyto trial yield similar or better results. Amgen would certainly pounce and help IMU to get this through FDA.
Competition like this is what drives BP to act. After all, the solid tumour market is huge. And nobody wants to be left behind.
Media Thread, page-14741
-
- There are more pages in this discussion • 371 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |